Poster
Other/Multi
SABCS 2024 | December 10-13, 2024
Breast Cancer
Real-world treatment patterns and clinical outcomes for patients with metastatic triple-negative breast cancer in the United States: An electronic health records observational study
Tiffany Traina
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Breast Cancer
Re-evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 0 or 1+ in metastatic breast cancer (mBC) samples to characterize the proportion of HER2-ultralow (IHC 0 with membrane staining)
Savitri Krishnamurthy
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Breast Cancer
The effectiveness of post–T-DXd treatments in patients with HER2-positive metastatic breast cancer: A nationwide Japanese cohort study (EN-SEMBLE)
Kazuki Nozawa
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Breast Cancer
Trastuzumab deruxtecan (T-DXd) in combination with capecitabine or capivasertib in patients with HER2-low metastatic breast cancer: A phase 1b, multicenter, open-label study (DESTINY-Breast08)
Komal Jhaveri
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Breast Cancer
Trastuzumab deruxtecan combined with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase Ib/II study (TROPHY)
Ying Fan
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Breast Cancer
Trastuzumab deruxtecan with pembrolizumab in previously treated HER2-expressing advanced or metastatic breast cancer: Interim analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106
Hope S. Rugo
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Breast Cancer
Valemetostat and trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-low, previously treated, unresectable or metastatic breast cancer
Sara M. Tolaney
Pages: 1  2